

# ATALANTE

*ATezolizumab and Avastin in LAte recurrenceNT diseaseE*


A randomized, double blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab

**Sponsor:** ARCAGY-GINECO


**Principal Investigator :** Pr Jean Emmanuel Kurtz; CHRU Strasbourg

**Scientific Coordinator:** Pr Eric Pujade-Lauraine

# STUDY DESIGN




# ATALANTE : ACCRUAL ON 15/05/2017



92 randomized patients / 119 screened (only in France)

32 sites actives / 39 sites opened



# ATALANTE : IMPORTANT INFORMATIONS

---

## Safety analyses

- 1<sup>st</sup> IDMC on 36 first patients who have received 1 cycle has been performed on March 2017
  - There are no safety concern in comparison with chemotherapy alone
- 2<sup>nd</sup> IDMC on 45 first patients who have received 2 cycles is planned in June 2017

## Amendement

Protocol was amended in April 2017 following the 1<sup>st</sup> IDMC.  
Approvals are expected in June.

Launch on an international level planned in September 2017